A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial
A Osman, Barbara Toson, Ganesh R. Naik, Sutapa Mukherjee, Martina Delbeck, Michael G. Hahn, Thomas Müller, Gerrit Weimann, Danny J. Eckert
Abstract
Preclinical findings in pigs and humans indicate that blocking potassium channels in the upper airway with topical nasal application increases pharyngeal dilator muscle activity and reduces upper airway collapsibility. In this study, BAY2586116 nasal spray (potassium channel blocker) reduced sleep apnea severity in those who had physiological improvement in upper airway collapsibility. BAY2586116 lowered the next morning's blood pressure. These findings highlight the potential for this novel therapeutic approach to improve sleep apnea in certain people.
Topics & Concepts
MedicineDilatorAnesthesiaApneaAirwayPlaceboSleep apneaRandomized controlled trialAntagonistObstructive sleep apneaInternal medicinePathologyAlternative medicineReceptorObstructive Sleep Apnea ResearchNeuroscience of respiration and sleepSleep and Wakefulness Research